FIG 6.

Anti-EBOV neutralizing antibody 13C6 blocks EBOVLP/Fluc/GP⁺ entry in mice. (A) Schematic diagram of the two administration methods in mice. In the “with incubation” method, VP40-normalized EBOVLP/Fluc/GP⁺ was mixed with MAb. After incubation, the mixtures were administered i.v. to BALB/c mice. In the “without incubation” method, MAb was given i.p. 2 h before EBOVLP/Fluc/GP⁺ inoculation. (B) In vivo inhibitory effects of 13C6 MAb administered using the two methods shown in panel A. An irrelevant MAb, 9B5, served as the antibody control. (C) MAb 13C6 blocks EBOVLP/Fluc/GP⁺ entry in mice. The indicated doses of 13C6 and the control MAb were evaluated by using the W-Inc method. In vivo bioluminescence imaging was performed at 12 h postinoculation. Representative images are shown. (D) Measurement of bioluminescence in mice from different treatment groups. Data from two independent experiments are shown. (B and D) The horizontal lines indicate the geometric means of each animal group. The significance of differences between groups was analyzed by nonparametric one-way ANOVA with Bonferroni's correction and shown as follows: ns, no significance (P ≥ 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001.